📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Anuh Pharma Facilities Found Compliant in EDQM Audit
Anuh Pharma Limited has successfully completed an audit by the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its manufacturing facilities in Tarapur, Maharashtra. The audit covered units E-17/3, E-17/4, and E-18, all of which were found to be compliant with global quality standards. This successful inspection is a significant milestone as it ensures the company's continued access to European markets for its pharmaceutical products. The compliance reaffirms the company's commitment to high regulatory standards, potentially boosting investor confidence in its export capabilities.
Key Highlights
EDQM audit successfully completed for three manufacturing units in Tarapur, Maharashtra.
Facilities E-17/3, E-17/4, and E-18 were found fully compliant with European quality standards.
The successful inspection reaffirms the company's adherence to global regulatory benchmarks.
Ensures uninterrupted access to the European market for the company's pharmaceutical products.
💼 Action for Investors
This regulatory clearance reduces operational risk and strengthens the company's export profile. Investors can maintain their positions as this secures a key revenue stream from the European region.
Anuh Pharma Q3 FY26 PAT Jumps 30% YoY to ₹13.45 Cr; Revenue Up 23.6%
Anuh Pharma reported a strong quarterly performance for the period ended December 31, 2025, with revenue from operations growing 23.6% YoY to ₹197.18 crore. Net profit for the quarter rose significantly by 30% YoY to ₹13.45 crore, aided by improved EBITDA margins which stood at 10.60%. On a sequential basis, the profit growth was even more pronounced, surging 76.7% compared to the preceding quarter (Q2 FY26). While the nine-month revenue is up 23%, the cumulative net profit remains lower than the previous year due to higher input costs incurred in the first half of the fiscal year.
Key Highlights
Revenue from operations increased by 23.6% YoY to ₹197.18 crore in Q3 FY26.
Net Profit (PAT) grew by 30% YoY to ₹13.45 crore, with a sharp 76.7% sequential recovery from Q2 FY26.
EBITDA margins improved to 10.60% in Q3 FY26 compared to 9.86% in the same quarter last year.
Earnings Per Share (EPS) for the quarter stood at ₹1.34, adjusted for the 1:1 bonus share issuance in July 2025.
The company recognized a one-time incremental obligation of ₹48.31 lakhs related to the implementation of New Labour Codes.
💼 Action for Investors
The strong quarterly recovery in margins and bottom-line growth indicates a positive shift in operational efficiency. Investors should monitor the sustainability of these margins in the upcoming quarter to confirm a full turnaround from the high-cost environment seen earlier in the year.
Anuh Pharma Q3 FY26 PAT Jumps 30% YoY to ₹13.45 Cr; Revenue Up 23.6%
Anuh Pharma reported a robust performance for Q3 FY26, with revenue from operations growing 23.6% YoY to ₹197.18 crore. Net profit for the quarter rose 30% YoY to ₹13.45 crore, marking a significant sequential recovery from ₹7.61 crore in Q2 FY26. EBITDA margins improved to 10.60% from 6.92% in the previous quarter, indicating better operational efficiency. However, cumulative 9-month PAT remains 15.8% lower than the previous year at ₹29.36 crore, despite a 22.9% growth in 9-month revenue.
Key Highlights
Revenue from operations increased 23.6% YoY to ₹19,717.81 Lakhs in Q3 FY26.
Net Profit (PAT) grew 30% YoY to ₹1,345.10 Lakhs, with a massive 76.7% sequential jump from Q2 FY26.
EBITDA margins expanded to 10.60% in Q3 FY26 compared to 9.86% in Q3 FY25 and 6.92% in Q2 FY26.
9M FY26 Revenue grew 22.9% to ₹56,954.02 Lakhs, though 9M PAT is down 15.8% YoY at ₹2,936.47 Lakhs.
The company recognized a one-time estimated obligation of ₹48.31 Lakhs due to the implementation of New Labour Codes.
💼 Action for Investors
The strong sequential recovery in margins and profitability suggests that the company has successfully navigated previous cost pressures. Investors should watch for the sustainability of these double-digit EBITDA margins in the upcoming quarters.